Vanadium in patients undergoing chronic haemodialysis

Area of Science:

• Clinical Chemistry
• Nephrology
• Toxicology

Background:

• Elevated serum vanadium levels are observed in patients undergoing chronic haemodialysis.
• The relationships between serum vanadium and other biomarkers in this population require investigation.

Purpose of the Study:

• To examine the correlations between serum vanadium and markers such as serum aluminium, beta 2-microglobulin, silicon, phosphate, red blood cell count, haemoglobin, and systolic blood pressure in chronic haemodialysis patients.
• To investigate vanadium transfer during the haemodialysis procedure.

Main Methods:

• Serum samples from 80 chronic haemodialysis patients were analyzed for vanadium and other specified markers.
• Measurements were taken before and after a 5-hour haemodialysis session.
• Vanadium levels in the dialysate and ultrafiltrate were compared to assess transfer.

Main Results:

• Serum vanadium levels in patients before haemodialysis were significantly higher (18.4 +/- 7.6 ng/ml) than normal values (0.4 +/- 0.2 ng/ml).
• Significant correlations were found between serum vanadium and serum aluminium, silicon, beta 2-microglobulin, phosphate, red blood cell count, haemoglobin, and systolic blood pressure.
• Vanadium transferred from blood to dialysate during haemodialysis, resulting in a significant decrease in serum vanadium levels post-haemodialysis (from 18.4 +/- 7.76 ng/ml to 13.0 +/- 5.30 ng/ml).

Conclusions:

• Elevated serum vanadium is associated with several clinical and biochemical parameters in chronic haemodialysis patients.
• Haemodialysis is an effective method for reducing serum vanadium levels in these patients.
• Further research is warranted to understand the clinical implications of these findings.